News

Jiangbo Pharma expects to complete the pilot production requirements and receive final distribution approval from SFDA in July 2010. Jiangbo Pharma plans to commence commercial distribution immediately following

Prasita is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in

GPSG Brazil is expected to use ‘Connects’ to enhance the quality control in its Sao Jose dos Campos pharmaceutical production facility in Sao Paulo Brazil. GPSG Brazil plans

Dermacyte Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development at Oxygen Biotherapeutics. It uses the company’s patented Oxycyte technology, an

Mr Wieland has over 30 years of senior financial experience with US-based public and private companies. He has served as the CFO of four NASDAQ-listed companies within the

Breckenridge Pharma is a pharmaceutical marketing, research and development company founded in 1983 that markets a range of generic prescription products in many therapeutic categories including several ValuBrand

According to Eisai, the arrangement covers the development of a combination antiemetic agent (in both oral and intravenous forms) containing netupitant (generic name), a neurokinin-1 (NK1) receptor antagonist,

Sucampo claimed that the trial met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data. The primary endpoint of

The trial is designed as a double-blind, placebo controlled, randomised, cross-over study comprising up to 60 non-smoking patients with moderate to severe COPD (GOLD II-III). Revotar said that